Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548473 | 0.82 | CYP4F2 (0.47) | CYP4F2CYP4A11 | |
| SCHEMBL6050114 | 0.82 | TSHR (0.39) | CYP4F2CYP4A11CCR2 | |
| SCHEMBL9481838 | 0.80 | TSHR (0.38) | CYP4F2CYP4A11CCR2 | |
| Ammonia Solution, Strong SCHEMBL27928496 | 0.80 | TSHR (0.38) | CYP4F2CYP4A11CCR2 | |
| SCHEMBL23270445 | 0.79 | TDP1 (0.33) | — | |
| SCHEMBL20880602 | 0.77 | TSHR (0.50) | — | |
| SCHEMBL631049 | 0.77 | CYP2C19 (0.38) | CCR2 | |
| SCHEMBL9247025 | 0.77 | CCR2 (0.33) | CCR2 | |
| SCHEMBL16869114 | 0.76 | CYP4F2 (0.39) | CYP4F2CYP4A11 | |
| SCHEMBL4453702 | 0.75 | CCR2 (0.36) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030868-B2 | Prodrugs of CGRP antagonists | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| CN-114945573-A | Prodrugs of myeloperoxidase inhibitors | 拜奥海芬治疗学有限公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-4041735-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | Biohaven Therapeutics Ltd. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| EP-3863629-A1 | PRODRUGS OF CGRP ANTAGONISTS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2021-08-18 | — | — | EP | disclosed |
| WO-2021072140-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072140-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | CALCRL, CALCA, CALCB | CYP4F2 1789/4885CYP4A11 1388/4885CCR2 1198/4885 |
| US-12030868-B2 | Prodrugs of CGRP antagonists | CALCRL, CALCA, CALCB | CYP4F2 1789/4885CYP4A11 1388/4885CCR2 1198/4885 |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | CYP4F2 2842/4885CYP4A11 3062/4885CCR2 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.